Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Expands Pharmaceutical Pipeline With $3.7 Bil Kos Acquisition

Executive Summary

Abbott's proposed $3.7 bil. acquisition of Kos Pharmaceuticals will help diversify Abbott's existing cardiovascular franchise, and could also expand its pipeline into respiratory diseases

You may also be interested in...



Lilly Expects Experience To Help Avoid Mistakes Of Pfizer’s Exubera Launch

Lilly's experience in the diabetes marketplace is one of the factors that fuels company optimism about its AIR inhaled insulin product, for which the company has an NDA submission goal of 2009, CEO Sidney Taurel told the Bear Stearns Healthcare Conference in New York, Sept. 11

Lilly Expects Experience To Help Avoid Mistakes Of Pfizer’s Exubera Launch

Lilly's experience in the diabetes marketplace is one of the factors that fuels company optimism about its AIR inhaled insulin product, for which the company has an NDA submission goal of 2009, CEO Sidney Taurel told the Bear Stearns Healthcare Conference in New York, Sept. 11

Abbott Cardiovascular Franchise Swells; Combo Waves Will Crest in 2009

Abbott plans to submit a fixed-dose statin-fenofibrate combination with AstraZeneca's Crestor in 2009, the company reported during a June 18 sales and earnings call

Related Content

UsernamePublicRestriction

Register

PS047741

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel